116 results
Page 5 of 6
UPLOAD
d8ktz rogmgez
23 Dec 20
Letter from SEC
12:00am
DRS
p8xyso66im78o422
18 Dec 20
Draft registration statement
12:00am
6-K
m0lhlqoc2m
17 Dec 20
Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
6:15am
6-K
1nzaeohfwm3yd4s q4hy
9 Dec 20
Current report (foreign)
4:23pm
6-K
y5oho9
9 Dec 20
Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
6:30am
6-K
dzulmef
8 Dec 20
Amryt Announces $40m Private Placement with Leading Biotech Investors
6:05am
6-K
qxlceabwqsdm
5 Nov 20
Amryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
7:55am
6-K
zpqtykzn01
3 Nov 20
Current report (foreign)
8:45am
6-K
so5etpg26wct2 q7
29 Oct 20
Amryt Announces Positive Results from Phase 3 Trial of Filsuvez® In Epidermolysis Bullosa
8:00am
6-K
pvfrfc2z b2s4jd6zcv
19 Oct 20
Current report (foreign)
8:00am
6-K
wlmpdz14aymvggbr5h
15 Sep 20
Current report (foreign)
8:31am
6-K
za44ule
9 Sep 20
Amryt Announces Positive Top Line Results from Pivotal Phase 3 “Ease” Trial of Filsuvez(r) In Epidermolysis Bullosa
8:23am
6-K
pmpffyeusrb8te4
11 Aug 20
Notification of Cancellation of Admission to Euronext Growth
10:04am
6-K
46ox3ph2
6 Aug 20
Amryt Announces Q2 2020 Results and Issues Positive Revenue Guidance for Fy 2020
9:43am
6-K
ehiyqb84nu ld
10 Jul 20
Current report (foreign)
9:46am
S-8
EX-5.1
duls804skbzx 3f
8 Jul 20
Registration of securities for employees
5:24pm
S-8
62np 2x8z6i0n
8 Jul 20
Registration of securities for employees
5:24pm
424B4
j49nsu3tf
8 Jul 20
Prospectus supplement with pricing info
4:05pm
F-1/A
mf17jxaz2tcm9 gpoj
7 Jul 20
Registration statement (foreign) (amended)
5:02pm
F-1/A
EX-5.1
p052c8v
7 Jul 20
Registration statement (foreign) (amended)
5:02pm